CA2765463C - Methods for treating or preventing fatigue - Google Patents
Methods for treating or preventing fatigue Download PDFInfo
- Publication number
- CA2765463C CA2765463C CA2765463A CA2765463A CA2765463C CA 2765463 C CA2765463 C CA 2765463C CA 2765463 A CA2765463 A CA 2765463A CA 2765463 A CA2765463 A CA 2765463A CA 2765463 C CA2765463 C CA 2765463C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- sleep
- fatigue
- test compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21908209P | 2009-06-22 | 2009-06-22 | |
| US61/219,082 | 2009-06-22 | ||
| PCT/US2010/039313 WO2011005473A2 (en) | 2009-06-22 | 2010-06-21 | Methods for treating or preventing fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2765463A1 CA2765463A1 (en) | 2011-01-13 |
| CA2765463C true CA2765463C (en) | 2018-10-09 |
Family
ID=43429751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2765463A Expired - Fee Related CA2765463C (en) | 2009-06-22 | 2010-06-21 | Methods for treating or preventing fatigue |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8741950B2 (instruction) |
| EP (1) | EP2445490B1 (instruction) |
| JP (3) | JP6095366B2 (instruction) |
| KR (3) | KR102021075B1 (instruction) |
| CN (2) | CN102481274A (instruction) |
| AU (1) | AU2010270971B2 (instruction) |
| BR (1) | BRPI1015233A2 (instruction) |
| CA (1) | CA2765463C (instruction) |
| IN (1) | IN2012DN00624A (instruction) |
| MX (1) | MX2012000034A (instruction) |
| RU (1) | RU2567801C2 (instruction) |
| TW (1) | TWI453014B (instruction) |
| WO (1) | WO2011005473A2 (instruction) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI419681B (zh) | 2005-06-08 | 2013-12-21 | Sk Biopharmaceuticals Co Ltd | 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 |
| JP6095366B2 (ja) * | 2009-06-22 | 2017-03-15 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | 疲労を治療又は予防するための方法 |
| WO2011055965A2 (en) | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| ES2554459T3 (es) | 2011-12-21 | 2015-12-21 | Innobioscience, Llc | Terapia combinada con interferón beta y andrografólidos para la esclerosis múltiple |
| TWI663971B (zh) | 2013-03-13 | 2019-07-01 | 南韓商愛思開生物製藥股份有限公司 | 猝倒症之治療 |
| KR20210152011A (ko) * | 2013-07-12 | 2021-12-14 | 에스케이바이오팜 주식회사 | 금연의 촉진 |
| US9226910B2 (en) | 2013-07-18 | 2016-01-05 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| PL3065751T3 (pl) * | 2013-11-08 | 2020-07-13 | Legacy Healthcare Ltd | Sposób leczenia raka i chorób współistniejących |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| CA3036071A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| SG11201903076QA (en) | 2016-10-06 | 2019-05-30 | Jazz Pharmaceuticals International Iii Ltd | Carbamoyl phenylalaninol compounds and uses therof |
| WO2018124769A1 (ko) * | 2016-12-30 | 2018-07-05 | 주식회사 동진쎄미켐 | 코팅 조성물 및 이로부터 제조되는 필름 |
| JP2020528075A (ja) | 2017-06-02 | 2020-09-17 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 過度の眠気を処置するための方法および組成物 |
| SG11202000817SA (en) | 2017-07-31 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Carbamoyl phenylalaninol analogs and uses thereof |
| JP7428480B2 (ja) * | 2019-06-06 | 2024-02-06 | 雪印メグミルク株式会社 | 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| KR102390194B1 (ko) | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| US20250032442A1 (en) * | 2021-11-16 | 2025-01-30 | Axsome Malta Ltd. | Methods and compositions for treating cognitive impairment |
| WO2025006965A1 (en) | 2023-06-29 | 2025-01-02 | Axsome Therapeutics, Inc. | Methods of administering solriamfetol to lactating women |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ314570A (en) | 1993-06-10 | 2000-11-24 | Lilly Co Eli | Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| WO1998015626A2 (en) | 1996-10-08 | 1998-04-16 | Institute Of Child Health | Mutant ciita molecule and uses thereof |
| JP4068154B2 (ja) * | 1996-10-10 | 2008-03-26 | エス ケー コーポレイション | Ｏ―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法 |
| AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US20040229951A1 (en) | 2003-05-15 | 2004-11-18 | Arthur Vanmoor | Method of treating fatigue by enhancing the effectiveness of the human immune system |
| RU2267319C2 (ru) * | 2003-07-15 | 2006-01-10 | Общество с ограниченной ответственностью "Интер-Кэр" | Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| AU2005302589B2 (en) * | 2004-10-28 | 2010-09-16 | Sk Biopharmaceuticals Co., Ltd. | Adjunctive therapy for depression |
| TWI419681B (zh) * | 2005-06-08 | 2013-12-21 | Sk Biopharmaceuticals Co Ltd | 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 |
| JP5298334B2 (ja) | 2005-06-22 | 2013-09-25 | エスケー ホルディングス カンパニー リミテッド | 性機能障害を治療する方法 |
| CA2616721C (en) | 2005-07-26 | 2014-01-21 | Janssen Pharmaceutica N.V. | Methods for treating substance-related disorders |
| BRPI0719275A2 (pt) | 2006-10-13 | 2014-04-29 | Janssen Pharmaceutica Nv | Composições de carbamatos de fenil-alquil-amino |
| JP6095366B2 (ja) * | 2009-06-22 | 2017-03-15 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | 疲労を治療又は予防するための方法 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| WO2011055965A2 (en) | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| TWI663971B (zh) * | 2013-03-13 | 2019-07-01 | 南韓商愛思開生物製藥股份有限公司 | 猝倒症之治療 |
| JP6215740B2 (ja) * | 2014-03-14 | 2017-10-18 | 本田技研工業株式会社 | 部品の締結構造 |
-
2010
- 2010-06-21 JP JP2012517622A patent/JP6095366B2/ja active Active
- 2010-06-21 EP EP10797541.9A patent/EP2445490B1/en active Active
- 2010-06-21 CA CA2765463A patent/CA2765463C/en not_active Expired - Fee Related
- 2010-06-21 KR KR1020177020249A patent/KR102021075B1/ko active Active
- 2010-06-21 IN IN624DEN2012 patent/IN2012DN00624A/en unknown
- 2010-06-21 AU AU2010270971A patent/AU2010270971B2/en active Active
- 2010-06-21 MX MX2012000034A patent/MX2012000034A/es active IP Right Grant
- 2010-06-21 RU RU2012101947/15A patent/RU2567801C2/ru active
- 2010-06-21 CN CN2010800277527A patent/CN102481274A/zh active Pending
- 2010-06-21 KR KR1020127001795A patent/KR20120098578A/ko not_active Ceased
- 2010-06-21 CN CN201710080968.3A patent/CN106727486A/zh active Pending
- 2010-06-21 BR BRPI1015233A patent/BRPI1015233A2/pt not_active Application Discontinuation
- 2010-06-21 KR KR1020197026173A patent/KR102173587B1/ko active Active
- 2010-06-21 US US13/379,793 patent/US8741950B2/en active Active
- 2010-06-21 WO PCT/US2010/039313 patent/WO2011005473A2/en not_active Ceased
- 2010-06-22 TW TW099120382A patent/TWI453014B/zh active
-
2014
- 2014-05-07 US US14/271,503 patent/US9464041B2/en active Active
-
2015
- 2015-07-03 JP JP2015134556A patent/JP6368285B2/ja active Active
-
2016
- 2016-09-16 US US15/268,060 patent/US9999609B2/en active Active
-
2018
- 2018-05-18 US US15/983,944 patent/US10507192B2/en active Active
- 2018-07-05 JP JP2018128318A patent/JP2018188450A/ja active Pending
-
2019
- 2019-10-31 US US16/670,382 patent/US20200061017A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10507192B2 (en) | Methods for treating or preventing fatigue using O-carbamoyl-phenylalaninol compounds | |
| EP2965756B1 (en) | Selective ep4 receptor antagonistic substance for treatment of cancer | |
| EP2349285B1 (en) | Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain | |
| US20160279160A1 (en) | Compositions comprising spicamycin derivatives and methods of use thereof | |
| HK1171657A (en) | Methods for treating or preventing fatigue | |
| HK1234314A1 (en) | Methods for treating or preventing fatigue | |
| US20220125844A1 (en) | Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy | |
| HK40003061B (en) | Selective ep4 receptor antagonistic substance for treatment of cancer | |
| HK1214763B (en) | Selective ep4 receptor antagonistic substance for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150413 |
|
| MKLA | Lapsed |
Effective date: 20210621 |